My vision is to develop a better understanding of signalling pathways that
regulate bone – immune – cancer cell crosstalk in inflammation and cancer.
The specific aims of my group’s research at the University of Sheffield
are to (a) uncover novel druggable pro-inflammatory signal
transduction pathways essential for the regulation of malignant - bone -
immune cell interactions, and (b) develop and test new
anti-inflammatory agents for the prevention and treatment of skeletal and
non-skeletal complications associated with cancer in patients with advanced
disease. My team at the University of Sheffield currently comprises of 1
postdoctoral research fellow and 4 Ph.D. and 2 MSc. students.
My Bone and Cancer Group at the Edinburgh Cancer Research UK
Centre, University of Edinburgh (2010 – 2014), developed a
model system to study the role of pro-inflammatory mediators in the
regulation of bone, immune and cancer cell crosstalk in vitro, ex
vivo and in animal models of metastatic bone disease. Our expertise
in these model systems have aided us to uncover novel pathways that play
a key role in the regulation of bone - cancer cell interaction, and led
to testing and development of a number of small molecule inhibitors of NFKB
activity for the treatment of rheumatoid arthritis and osteolysis. During
this period, I have supervised 2 postdoctoral research fellows and 4 Ph.D.
students with great success. My work in the area of cancer associated bone
disease has produced 3 last-author articles published in JBMR, JBC and Br.
J. Pharmacology, 1 first-author article published in Molecular Cancer
Therapeutics and 6 abstracts.
In my early postdoctoral training period working at the University of
Edinburgh (2005 – 2010) and in Professor S. Ralston’s group at the
University of Aberdeen (2001 - 2005), the focus of my research was the
discovery of novel anti-resorptive agents for the prevention and
treatment for excessive bone loss. My PhD thesis yielded a number
of patents for novel anti-resorptive agents and my work on the role
of cannabinoids in bone biology was published in a number of
reputable journals including Nature Medicine and Cell Metabolism,
and attracted significant funding. During this period, I published 16
original research articles, 3 reviews and 2 book chapters. I was awarded
the Ian Boyle award and received an AMGEN/ECTS Fellowship. I
won 5 young investigator awards, received numerous travel awards,
and submitted 16 abstracts to international conferences - 13 of which
were chosen for oral presentations.